Celcuity Inc (CELC)
$18.73
Performance
- $18.60$19.77$18.73
0.69%
Downside
Day's Volatility :5.92%
Upside
5.26%
- $8.39$22.19$18.73
55.21%
Downside
52 Weeks Volatility :62.19%
Upside
15.59%
Returns
| Period | Celcuity Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 20.29% | 6.5% | 0.0% |
6 Months | 30.01% | 7.1% | 0.0% |
1 Year | 93.14% | 9.8% | 0.0% |
3 Years | -7.4% | 14.2% | -20.2% |
Highlights
Market Capitalization | 672.2M |
Book Value | $4.35 |
Earnings Per Share (EPS) | -2.85 |
Wall Street Target Price | 28.83 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -26.97% |
Return On Equity TTM | -57.17% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -76.0M |
Diluted Eps TTM | -2.85 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.75 |
EPS Estimate Next Year | -3.53 |
EPS Estimate Current Quarter | -0.71 |
EPS Estimate Next Quarter | -0.74 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 53.92%
Technicals Summary
Sell
Neutral
Buy
Celcuity Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Celcuity Inc | 19.46% | 30.01% | 93.14% | -7.4% | -9.46% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Celcuity Inc | NA | NA | NA | -2.75 | -0.57 | -0.27 | NA | 4.35 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Celcuity Inc | Buy | $672.2M | -9.46% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Celcuity Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 193.9%
Institutional Holdings
Perceptive Advisors LLC
6.73%Morgan Stanley - Brokerage Accounts
6.69%Soleus Capital Management, L.P.
4.93%COMMODORE CAPITAL LP
4.43%Baker Bros Advisors LP
4.42%Eventide Asset Management, LLC
3.96%
Company Information
celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform. we directly assess the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo to determine whether a drug therapy has the intended effect on those cells. the patient specific cellular data we provide offers clinicians and pharmaceutical companies unique insight into a patient's response to a drug therapy, and it will change the paradigm of personalized medicine.
Organization | Celcuity Inc |
Employees | 55 |
CEO | Mr. Brian F. Sullivan |
Industry | Commercial Services |
Discover More
A Spac I Acquisition Corp
$18.73
-2.19%
Keyarch Acquisition Corp
$18.73
-2.19%
Connexa Sports Technologies Inc
$18.73
-2.19%
Us Value Etf
$18.73
-2.19%
First Wave Biopharma Inc
$18.73
-2.19%
Global X Msci Next Emerging
$18.73
-2.19%
Fat Projects Acquisition Corp
$18.73
-2.19%
Capital Link Global Fintech
$18.73
-2.19%
Applied Uv Inc
$18.73
-2.19%